Optimizing Outcomes of Endovascular Aneurysm Repair in Patients With CKD – Endovascular Today
Factors affecting loss of renal function, defining acute kidney injury, and measures to minimize the risk of renal injury.
Related Articles
Ostial Becomes Verge Medical and Acquires Crossfire’s Wavella Technology – Cardiac Interventions Today
March 17, 2025—Ostial Corporation, a California-based medical device company focused on aorto-ostial interventions, announced its new identity a
UFE: Reaching More Patients and Meeting Their Needs – Endovascular Today
A conversation about awareness and access needs for uterine fibroid embolization, including what is holding it back from the mainstream, the intersection between disparities and…
Embolization Evolution
In This Issue Parag J. Patel, MD, summarizes our latest feature on the embolization evolution, where expert operators share their technical tips and opinions and…
Reflow Medical Expands With New European Subsidiary – Cardiac Interventions Today
March 6, 2025—Reflow Medical, Inc., which is headquartered in San Clemente, California, announced the opening of its European subsidiary in Land
Stryker’s Inari Medical Launches Artix Thrombectomy System – Endovascular Today
March 6, 2025—Inari Medical announced the launch of its Artix thrombectomy system for arterial thromboembolism. According to the company, which
Philips Recalls, Removes, and Discontinues Distribution of Tack Endovascular System – Endovascular Today
March 6, 2025—The FDA advised this week that Philips is recalling the Tack endovascular systems because of challenges experienced by customers d
J&J MedTech Launches Cereglide 92 Catheter to Treat Acute Ischemic Stroke – Endovascular Today
February 14, 2024—Johnson & Johnson MedTech recently launched their Cereglide 92 catheter system for the treatment of acute ischemic stroke.
CVRx Barostim Demonstrates Reduction in Health Care Use in Real-World Data – Endovascular Today
February 12, 2025—CVRx, Inc. announced new real-world evidence demonstrating that use of the company’s Barostim implant was associated wit
Guerbet’s Lipiojoint Liquid Embolic Granted FDA Breakthrough Device Status – Endovascular Today
February 10, 2025—Guerbet announced that its Lipiojoint transient liquid embolic agent received Breakthrough Device status from the United State
Digital Health in DVT: What Would Truly Help Guide Care and Research? – Endovascular Today
Insights into the digital tools that can help improve patient engagement and advance understanding in deep vein thrombosis care.